Pepromene Bio: Progress In B-nhl Trial With Pmb-ct01

By Author: Ben Gross
Total Articles: 460
Comment this article

PeproMene Bio, Inc., a clinical-stage biotech company, has announced the successful completion of the first dose cohort in its phase 1 clinical trial for PMB-CT01 (BAFFR-CAR T Cells), a novel therapy designed to treat relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL). This milestone was achieved without any observed Dose Limiting Toxicity (DLT), allowing the trial to proceed to the next phase.

The trial, known as PMB-102, is being conducted at City of Hope, a leading cancer research and treatment institution. PeproMene licensed the intellectual property for PMB-CT01 from City of Hope. In the first cohort, 50x106 PMB-CT01 was administered, and the therapy was well-tolerated with minimal toxicity. Notably, all three patients in this cohort showed positive responses to treatment, with a 100% Overall Response Rate at one month post-treatment, including two Complete Responses and one Partial Response.

PMB-CT01 represents a potential breakthrough in treating B-cell malignancies. Unlike previous therapies, it targets BAFF-R (B Cell Activating Factor Receptor), a receptor found primarily on B cells, making ...
... it difficult for tumor cells to evade immune responses through the loss of this receptor. This unique approach offers hope for patients who have relapsed after CD19 CAR T-cell therapy, addressing an unmet medical need.

The promising results in this early stage of the trial align with preclinical research data from City of Hope, demonstrating PMB-CT01's ability to overcome CD19 antigen loss in B-cell malignancies. PeproMene's commitment to advancing this therapy underscores its potential as a new option for patients with B-cell lymphoma.

PeproMene Bio, Inc. is based in Irvine, California, and is focused on developing innovative therapies for cancers and immune disorders. PMB-CT01 is currently being investigated in phase 1 clinical trials for B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin's lymphoma (B-NHL). Additionally, PeproMene is working on other promising therapies, including BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells.

More Information : https://www.techdogs.com/tech-news/pr-newswire/pepromene-bio-inc-announced-completion-of-the-first-dose-cohort-and-opening-of-the-second-dose-cohort-in-its-b-cell-non-hodgkin-lymphoma-b-nhl-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells